Pipeline

KER-012 is an investigational modified activin receptor type IIB (ActRIIB) fusion protein being developed for the treatment of pulmonary arterial hypertension (PAH) and cardiovascular disorders. KER-012 is designed to normalize blood vessel thickness and heart function by inhibiting select TGF-β ligands, including activin A, activin B and myostatin (GDF8)—which stimulate smooth muscle hypertrophy and fibrosis—while sparing the bone morphogenic protein (BMP) ligands. For more information about our ongoing Phase 2 clinical trial in PAH, click here.

KER-065 is an investigational selective activin receptor ligand trap being developed for the treatment of neuromuscular disorders. KER-065 is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A to increase skeletal muscle and bone mass, increase fat metabolism and reduce fibrosis. We have initiated a Phase 1 clinical trial of KER-065 in a healthy volunteer adult population.

Elritercept (KER-050) is an investigational activin receptor type IIA (ActRIIA) fusion protein designed to inhibit select TGF-β ligands, including activin A. Based on data from our completed Phase 1 clinical trial and multiple preclinical studies, we believe elritercept has the potential to increase red blood cell and platelet production by acting across the spectrum of cellular differentiation and maturation in hematopoiesis while also improving bone health.

Elritercept is being developed for the treatment of ineffective hematopoiesis in myelodysplastic syndromes (MDS) and myelofibrosis (MF), where the impact of the disease in the bone marrow microenvironment can contribute to anemia, thrombocytopenia, neutropenia and an increased risk of acute myeloid leukemia.